Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India
NCT ID: NCT04288895
Last Updated: 2022-03-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
400 participants
INTERVENTIONAL
2020-02-20
2022-03-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
NCT01255787
Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
NCT00735709
Real-life Effectiveness of Vortioxetine in Depression
NCT03555136
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
NCT01163266
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
NCT00707980
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vortioxetine
flexible-dose
Vortioxetine
5 - 20 mg/day flexible-dose vortioxetine, tablets, orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vortioxetine
5 - 20 mg/day flexible-dose vortioxetine, tablets, orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient has a CGI-S ≥4 at screening.
Exclusion Criteria
* The patient previously received vortioxetine.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
H. Lundbeck A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ratandeep Multispecialty Hospital (IN1002)
Ahmedabad, Gujarat, India
MITR Foundation 1 (IN1013)
Ahmedabad, Gujarat, India
BJ Medical College and Civil Hospital (IN028)
Ahmedabad, Gujarat, India
Shree Hatkesh Health Foundation (IN1016)
Jūnāgadh, Gujarat, India
Nagecha Hospital, Creative Chamber (IN1015)
Rajkot, Gujarat, India
Divyam Clinic (IN1025)
Surat, Gujarat, India
GMERS Medical College and Hospital,Department of Psychiatry (IN1004)
Vadodara, Gujarat, India
People Tree Hospitals (IN1027)
Bengaluru, Karnataka, India
Vinaya Hospital & Research Centre (IN1007)
Mangalore, Karnataka, India
Mangala Hospital & Mangala Kidney Foundation (IN1006)
Mangalore, Karnataka, India
K. S. Hegde Medical Academy (IN1003)
Mangalore, Karnataka, India
Department of Psychiatry K R Hospital Mysore Medical College and Research Institute (IN1020)
Mysuru, Karnataka, India
IQRAA International Hospital & Research Centre (IN030)
Kozhikode, Kerala, India
Society for Psychiatric Update and Research, Shanti Nursing Home (IN1008)
Aurangabad, Maharashtra, India
Arneja Heart and Multispeciality Hospital (IN1022)
Nagpur, Maharashtra, India
Central Institute of Behavioural Sciences (IN1019)
Nagpur, Maharashtra, India
Chopda Medicare & Research Centre (IN023)
Nashik, Maharashtra, India
Lata Mangeshkar Medical Foundation's (IN1001)
Pune, Maharashtra, India
Oyster and Pearl Hospital (IN1014)
Pune, Maharashtra, India
Dayanand Medical College and Hospital (IN024)
Ludhiana, Punjab, India
ASHA hospital (IN1018)
Hyderabad, Telangana, India
Deva Institute of Healthcare and Research PVT ltd. (IN1005)
Varanasi, Uttar Pradesh, India
Institute of Post Graduate Medical Education and Research (IN1026)
Kolkata, West Bengal, India
Maharaja Agarsen Hospital (IN1021)
Delhi, , India
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Adair M, Bose R, Schmidt SN. Safety and effectiveness of vortioxetine in patients with major depressive disorder in a real-life clinical setting in India: results from an interventional, flexible-dose study. Curr Med Res Opin. 2024 Sep;40(9):1637-1645. doi: 10.1080/03007995.2024.2382773. Epub 2024 Aug 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17775A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.